BR112013018057A2 - composição que compreende opc e ômega-3 para prevenção e/ou inibição do desenvolvimento de retinopatia diabética - Google Patents

composição que compreende opc e ômega-3 para prevenção e/ou inibição do desenvolvimento de retinopatia diabética

Info

Publication number
BR112013018057A2
BR112013018057A2 BR112013018057A BR112013018057A BR112013018057A2 BR 112013018057 A2 BR112013018057 A2 BR 112013018057A2 BR 112013018057 A BR112013018057 A BR 112013018057A BR 112013018057 A BR112013018057 A BR 112013018057A BR 112013018057 A2 BR112013018057 A2 BR 112013018057A2
Authority
BR
Brazil
Prior art keywords
composition
opc
omega
inhibiting
development
Prior art date
Application number
BR112013018057A
Other languages
English (en)
Inventor
Hadj-Slimane Reda
Hadj-Slimane Tewfik
Lepelletier Yves
Original Assignee
Visiotact Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visiotact Pharma filed Critical Visiotact Pharma
Publication of BR112013018057A2 publication Critical patent/BR112013018057A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composição que compreende opc e ômega-3 para prevenção e/ou inibição do desenvolvimento de retinopatia diabética essa invenção está relacionada a uma composição que compreende oligoproantocianidinas (opc) e ácidos graxos ômega-3, para uso na prevenção ou estabilização do desenvolvimento e/ou da progressão de uma condição ocular relacionada ao diabetes em um indivíduo; essa invenção inclui um alimento funcional, uma composição nutracêutica ou um suplemsneto alimentar ou dietético que compreende a referida composição; essa invenção também está relacionada a uma composição farmacêutica ou a um produto veterinário que compreende oligoproantocianidinas (opc) e ácidos graxos ômega-3.
BR112013018057A 2011-01-14 2012-01-13 composição que compreende opc e ômega-3 para prevenção e/ou inibição do desenvolvimento de retinopatia diabética BR112013018057A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305044.7A EP2476425B1 (en) 2011-01-14 2011-01-14 Composition comprising OPC and Omega-3 for preventing and/or inhibiting the development of diabetic retinopathy
PCT/EP2012/050505 WO2012095525A1 (en) 2011-01-14 2012-01-13 Composition comprising opc and omega-3 for preventing and/or inhibiting the development of diabetic retinopathy

Publications (1)

Publication Number Publication Date
BR112013018057A2 true BR112013018057A2 (pt) 2019-09-24

Family

ID=43754740

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013018057A BR112013018057A2 (pt) 2011-01-14 2012-01-13 composição que compreende opc e ômega-3 para prevenção e/ou inibição do desenvolvimento de retinopatia diabética

Country Status (5)

Country Link
US (1) US20130295199A1 (pt)
EP (2) EP2476425B1 (pt)
BR (1) BR112013018057A2 (pt)
CA (1) CA2823607A1 (pt)
WO (1) WO2012095525A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2800563T3 (pl) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc. Wzbogacone w DPA kompozycje wielonienasyconych kwasów tłuszczowych omega-3 w postaci wolnego kwasu
JP6173437B2 (ja) 2012-05-07 2017-08-02 オムセラ・ファーマシューティカルズ・インコーポレイテッド スタチン及びω−３脂肪酸の組成物
CA2941970A1 (en) * 2014-03-13 2015-09-17 Retrotope, Inc. Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances
EP3187185A4 (en) * 2014-08-29 2018-04-11 Project PM Co., Ltd. Pharmaceutical composition formed by combining pyridoxamine compound and thiamine compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1021177A4 (en) * 1997-02-04 2002-05-15 John V Kosbab COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF VASCULAR DEGENERATIVE DISEASES
EP1214893A1 (en) 2000-12-16 2002-06-19 Aventis Pharma Deutschland GmbH Health promoting compositions
WO2002047493A2 (en) * 2000-12-16 2002-06-20 Aventis Pharma Deutschland Gmbh Health promoting compositions
US8017147B2 (en) 2008-04-07 2011-09-13 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance

Also Published As

Publication number Publication date
EP2476425B1 (en) 2014-03-19
WO2012095525A1 (en) 2012-07-19
EP2476425A1 (en) 2012-07-18
US20130295199A1 (en) 2013-11-07
CA2823607A1 (en) 2012-07-19
EP2663319A1 (en) 2013-11-20

Similar Documents

Publication Publication Date Title
CU20140151A7 (es) Composición farmacéutica útil en la prevención de un evento cardiovascular mayor
BR112015014372A2 (pt) inibidores de autotaxina
BR112012023267A2 (pt) Método para alterar a composição dos ácidos graxos da membrana cerebral, método para aperfeiçoar o desempenho cognitivo em um indivíduo humano e uso de uma composição
BR112013012617A2 (pt) uso de glicosidase na preparação de um produto do leite
BR112015002372A2 (pt) composições e métodos para a redução do teor de álcool no sangue
BR112014019927A8 (pt) fórmula nutricional, método de preparação da referida fórmula antes da sua ingestão por um indivíduo, uso da referida fórmula, dispositivo para prepará-la e recipiente
MY176018A (en) Composition useful for the treatment of lipid metabolism disorders
ECSP15001892A (es) Manejo dietético de la enfermedad celíaca y alergia a los alimentos
WO2012038512A3 (en) Composition comprising sod, lutein and zeaxanthin
BR112013018057A2 (pt) composição que compreende opc e ômega-3 para prevenção e/ou inibição do desenvolvimento de retinopatia diabética
AR090084A1 (es) Producto acuoso que comprende microcapsulas que contienen aceite, y metodo para su fabricacion
MA39157A1 (fr) Composition utile pour favoriser la fertilite feminine
BR112017013004A8 (pt) Produto frito obtido a partir de uma composição para um produto frito, uso de uma farinha de microalgas como substituta da gordura e método de preparação de um produto frito
BR112013015634B8 (pt) composição que compreende gordura, proteína e carboidratos, uso da composição, uso de fibras alimentares, processo para preparação de uma fórmula infantil e processo para preparação da composição
BR112018000242A2 (pt) composições nutricionais contendo fosfatidiletanolamina, esfingomielina e ácido doco-saexaenóico
MA40815A1 (fr) Composition pour la sante oculaire
BR112018002036A2 (pt) método para o controle das pragas de um vegetal de algodão e utilização de um ou mais componentes da árvore de ginkgo
BR112017016445A2 (pt) microcápsula, processo para preparar uma microcápsula, produto, e, comprimido, suplemento dietético ou alimento.
ECSP15002095A (es) Formulación farmacéutica
BR112014027738A2 (pt) ácido graxo de talóleo que é modificado por saponificação para uso, suplemento alimentar, e composto alimentar
BR112012026346A2 (pt) formulações inovadoras de ingredientes (s) ativo(s) de origem vegetal ou seus análogos sintéticos ou de extrato(s) de origem vegetal que os inclui, e de lacitina
BR112013028820A2 (pt) alimento medicinal para declínio cognitivo
CO2017005383A2 (es) Composiciones inhibidoras
BR112013002832A2 (pt) composição compreendendo retinol, um precursor ou um produto de reação do mesmo e um extrato vegetal de pelo menos uma planta de camomila para o tratamento de câncer
BR112014003545A8 (pt) método para transformar uma refeição

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.